847359-07-3Relevant articles and documents
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor
Isabel, Elise,Bateman, Kevin P.,Chauret, Nathalie,Cromlish, Wanda,Desmarais, Sylvie,Duong, Le T.,Falgueyret, Jean-Pierre,Gauthier, Jacques Yves,Lamontagne, Sonia,Lau, Cheuk K.,Leger, Serge,LeRiche, Tammy,Levesque, Jean-Francois,Li, Chun Sing,Masse, Frederic,McKay, Daniel J.,Mellon, Christophe,Nicoll-Griffith, Deborah A.,Oballa, Renata M.,Percival, M. David,Riendeau, Denis,Robichaud, Joel,Rodan, Gideon A.,Rodan, Sevgi B.,Seto, Carmai,Therien, Michel,Truong, Vouy Linh,Wesolowski, Gregg,Young, Robert N.,Zamboni, Robert,Black, W. Cameron
scheme or table, p. 887 - 892 (2010/08/22)
MK-0674 is a potent and selective cathepsin K inhibitor from the same structural class as odanacatib with a comparable inhibitory potency profile against Cat K. It is orally bioavailable and exhibits long half-life in pre-clinical species. In vivo studies
